Eloi Kpamegan

发表

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

J. Stoddard, V. Shinde, G. Glenn, 2017, Immunity & Ageing.

A Ballooned Beta-Logistic Model

N. Flournoy, Eloi Kpamegan, Min-Jeong Yi, 2017 .

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.

G. Glenn, L. Fries, D. N. Thomas, 2017, Vaccine.

Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs.

G. Glenn, L. Fries, Eloi Kpamegan, 2015, Vaccine.

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.

Bin Zhou, G. Glenn, S. Boddapati, 2013, Vaccine.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Z. Wei, G. Glenn, L. Fries, 2013, Vaccine.

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.

B. Landry, J. McClain, J. Sadoff, 2012, Vaccine.

$D$-optimal designs given a bivariate probit response function

Eloi Kpamegan, 1998 .

H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans

G. Glenn, S. Khurana, J. Manischewitz, 2011, Journal of Virology.

Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts

L. Mofenson, M. Lindegren, M. Fowler, 2000 .

A new bounded log-linear regression model

Haiying Wang, N. Flournoy, Eloi Kpamegan, 2013, Metrika.

Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus

Eloi Kpamegan, H. Dean, E. Nascimento, 2021, International journal of molecular sciences.

A new bounded log-linear regression model

Haiying Wang, N. Flournoy, Eloi Kpamegan, 2014 .

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bin Zhou, G. Glenn, Haifeng Song, 2016, Vaccine.

Mode of Delivery and Postpartum Morbidity Among HIV‐Infected Women: The Women and Infants Transmission Study

Eloi Kpamegan, C. Zorrilla, S. Landesman, 2001, Journal of acquired immune deficiency syndromes.

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

G. Glenn, L. Fries, D. N. Thomas, 2016, The Journal of infectious diseases.

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

J. Stoddard, V. Shinde, G. Glenn, 2017, Immunity & Ageing.

Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry.

G. Kaplan, T. Scriba, G. Hussey, 2015, Journal of immunological methods.

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.

G. Glenn, L. Fries, D. N. Thomas, 2017, Vaccine.